iX Biopharma

Update

iX Biopharma disposes of Australian lab testing business for $12 mil after 2Q losses

SINGAPORE (Feb 18): iX Biopharma is selling Chemical Analysis, its laboratory testing business in Australia, to Eurofins Australia New Zealand Holding for A$12.5 million ($12 million).  

Results

iX Biopharma 2Q losses widen 11% to $3.6 mil

SINGAPORE (Feb 12): Specialty pharmaceutical and nutraceutical firm iX Biopharma has reported a net loss of $3.6 million in 2Q19, an increase of 11% compared to a net loss of $3.2 million in 2Q18.

In print this week

Bringing home the bacon

SINGAPORE (Feb 1): The Edge Singapore has assembled the annual portfolio of 10 stocks, done in conjunction with the Lunar New Year.

iXBiopharma's Wafesil granted regulatory approval for treatment of male erectile dysfunction in Australia

SINGAPORE (June 19): iX Biopharma says the Australia’s regulatory authority, Therapeutic Goods Administration (TGA), has given the go-ahead for the use of Wafesil to treat of male erectile dysfunct

Results

iX Biopharma 3Q loss widens to $4.3 mil on forex losses, higher cost of sales and launch expenses

SINGAPORE (May 9): Specialty pharmaceutical company iX Biopharma recorded a net loss of $4.3 million in 3Q18, against a net loss of $2.9 million in 3Q17.

Results

iX Biopharma 2Q losses widen to $3.24 mil; secures WaferiX patent in China

SINGAPORE (Feb 8): iX Biopharma announced 2Q losses widened nearly fivefold to $3.24 million from $0.67 million a year ago.

In print this week

Pharma developer iX Biopharma banks on online supplement sales for growth, profits

SINGAPORE (Dec 18): Catalist-listed iX Biopharma has launched a line of nutraceuticals that could help it turn a profit sooner than it could have done through the development of its pain management

In print this week

Can iX Biopharma's new line help lift its limp stock?

SINGAPORE (Dec 15):  Catalist-listed iX Biopharma has launched a line of nutraceuticals – dietary supplements and fortified food products – that could help it turn a profit sooner than it could hav

Results

iX Biopharma sinks deeper into the red in 1Q on higher expenses

SINGAPORE (Nov 8): Specialty pharmaceutical firm iX Biopharma saw its net losses quadruple to $3.2 million for the 1Q18 ended September, widening from a net loss of $0.8 million a year ago.

iX Biopharma secures European patent for drug delivery technology

SINGAPORE (Oct 23): Specialty pharmaceutical firm iX Biopharma announced Monday that it has secured a European patent for its WaferiX drug delivery technology.

×